– Expands Board of Directors with Two New Appointments – Wilmington, DE – August 24, 2020 – Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, today announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional
– Advances lead product into clinic and additional compounds into preclinical development – David Mauro, MD, PhD, as Chief Medical Officer, and Brian Piper, MBA, as Chief Financial Officer, join management team led by Founder and CEO, Kris Vaddi, PhD Wilmington, DE – June 12, 2019 – Prelude
